Evaluating Effects of EPO in Rodent Behavioral Assays Related to Depression

  • Catharine H. Duman
  • Samuel S. Newton
Part of the Methods in Molecular Biology book series (MIMB, volume 982)


The cytokine erythropoietin (EPO) is an important regulator of hematopoesis and has well-known tissue protective properties. Neurotrophic action is implicated as mechanistically important in the treatment of depression, and neurotrophic actions of EPO suggest potential therapeutic utility of an EPO-like mechanism in depressive disorder. Rodent behavioral models that are responsive to clinically used antidepressants as well as to neurotrophic compounds can be used to assess potential antidepressant properties of EPO and EPO-like compounds. Rodent models described here are the forced-swim test (FST), a hyponeophagia test and the novel object recognition test. Each of these models provides different information and relevance to depression and each can be tested with EPO and similar compounds.

Key words

EPO CEPO Depression Behavior Swim test Object recognition Hyponeophagia 



We thank Dr. Shannon Gourley and Monica Sathyanesan for their assistance in conducting the novel object recognition test. This work is supported by USHPS grant MH 078132 and the Connecticut Mental Health Center.


  1. 1.
    Masuda S et al (1993) Functional erythropoietin receptor of the cells with neural characteristics. Comparison with receptor properties of erythroid cells. J Biol Chem 268(15):11208–11216PubMedGoogle Scholar
  2. 2.
    Konishi Y et al (1993) Trophic effect of erythropoietin and other hematopoietic factors on central cholinergic neurons in vitro and in vivo. Brain Res 609(1–2):29–35PubMedCrossRefGoogle Scholar
  3. 3.
    Morishita E et al (1997) Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons, and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 76(1):105–116PubMedCrossRefGoogle Scholar
  4. 4.
    Brines M et al (2000) Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury. Proc Natl Acad Sci U S A 97(19):10526–10531PubMedCrossRefGoogle Scholar
  5. 5.
    Brines M, Cerami A (2005) Emerging biological roles for erythropoietin in the nervous system. Nat Rev Neurosci 6(6):484–494PubMedCrossRefGoogle Scholar
  6. 6.
    Leist M et al (2004) Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305(5681):239–242PubMedCrossRefGoogle Scholar
  7. 7.
    Brines M et al (2008) Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci U S A 105:10925–10930PubMedCrossRefGoogle Scholar
  8. 8.
    Duman RS, Heninger GR, Nestler EJ (1997) A molecular and cellular theory of depression. Arch Gen Psychiatry 54(7):597–606PubMedCrossRefGoogle Scholar
  9. 9.
    Girgenti MJ et al (2009) Erythropoietin induction by electroconvulsive seizure, gene regulation, and antidepressant-like behavioral effects. Biol Psychiatry 66(3):267–274PubMedCrossRefGoogle Scholar
  10. 10.
    Miskowiak K et al (2008) Erythropoietin improves mood and modulates the cognitive and neural processing of emotion 3 days post administration. Neuropsychopharmacology 33(3):611–618PubMedCrossRefGoogle Scholar
  11. 11.
    Porsolt RD, Bertin A, Jalfre M (1977) Behavioral despair in mice: a primary screening test for antidepressants. Arch Int Pharmacodyn Ther 229(2):327–336PubMedGoogle Scholar
  12. 12.
    Porsolt RD, Le Pichon M, Jalfre M (1977) Depression: a new animal model sensitive to antidepressant treatments. Nature 266(5604):730–732PubMedCrossRefGoogle Scholar
  13. 13.
    Porsolt RD, Bertin A, Jalfre M (1978) “Behavioural despair” in rats and mice: strain differences and the effects of imipramine. Eur J Pharmacol 51(3):291–294PubMedCrossRefGoogle Scholar
  14. 14.
    Borsini F, Meli A (1988) Is the forced swimming test a suitable model for revealing antidepressant activity? Psychopharmacology (Berl) 94:147–160CrossRefGoogle Scholar
  15. 15.
    Shirayama Y et al (2002) Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 22(8):3251–3261PubMedGoogle Scholar
  16. 16.
    Duman CH et al (2009) Peripheral insulin-like growth factor-I produces antidepressant-like behavior and contributes to the effect of exercise. Behav Brain Res 198(2):366–371PubMedCrossRefGoogle Scholar
  17. 17.
    Detke MJ, Rickels M, Lucki I (1995) Active behaviors in the rat forced swimming test differentially produced by serotonergic and noradrenergic antidepressants. Psychopharmacology (Berl) 121(1):66–72CrossRefGoogle Scholar
  18. 18.
    Lucki I (1997) The forced swimming test as a model for core and component behavioral effects of antidepressant drugs. Behav Pharmacol 8:523–532PubMedCrossRefGoogle Scholar
  19. 19.
    Willner P (1990) Animal models of depression: an overview. Pharmacol Ther 45:425–455PubMedCrossRefGoogle Scholar
  20. 20.
    Thiébot M-H, Martin P, Puech AJ (1992) Animal behavioural studies in the evaluation of antidepressant drugs. Br J Psychiatry 160:44–50Google Scholar
  21. 21.
    Bodnoff SR et al (1988) The effects of chronic antidepressant treatment in an animal model of anxiety. Psychopharmacology (Berl) 95(3):298–302CrossRefGoogle Scholar
  22. 22.
    Bodnoff SR et al (1989) A comparison of the effects of diazepam versus several typical and atypical anti-depressant drugs in an animal model of anxiety. Psychopharmacology (Berl) 97(2):277–279CrossRefGoogle Scholar
  23. 23.
    Dulawa SC, Hen R (2005) Effects of chronic fluoxetine in animal models of anxiety and depression. Neurosci Biobehav Rev 29(4–5):771–783PubMedCrossRefGoogle Scholar
  24. 24.
    Kaufman J, Charney D (2000) Comorbidity of mood and anxiety disorders. Depress Anxiety 12(Suppl 1):69–76PubMedCrossRefGoogle Scholar
  25. 25.
    Ressler KJ, Nemeroff CB (2000) Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress Anxiety 12(Suppl 1):2–19PubMedCrossRefGoogle Scholar
  26. 26.
    Serretti A et al (2009) Common genetic, clinical, demographic and psychosocial predictors of response to pharmacotherapy in mood and anxiety disorders. Int Clin Psychopharmacol 24(1):1–18PubMedCrossRefGoogle Scholar
  27. 27.
    Ennaceur A, Delacour J (1988) A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav Brain Res 31(1):47–59PubMedCrossRefGoogle Scholar
  28. 28.
    Miskowiak K et al (2008) Differential effects of erythropoietin on neural and cognitive measures of executive function 3 and 7 days post-administration. Exp Brain Res 184(3):313–321PubMedCrossRefGoogle Scholar
  29. 29.
    Ehrenreich H et al (2004) Erythropoietin: a candidate compound for neuroprotection in schizophrenia. Mol Psychiatry 9(1):42–54PubMedGoogle Scholar
  30. 30.
    Morgensen J et al (2008) Erythropoietin improves spatial delayed alternation in a T-maze in rats subjected to ablation of the prefrontal cortex. Brain Res Bull 77(1):1–7CrossRefGoogle Scholar
  31. 31.
    Mun KC, Golper TA (2000) Impaired biological activity of erythropoietin by cyanate carbamylation. Blood Purif 18:13–17PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2013

Authors and Affiliations

  • Catharine H. Duman
    • 1
  • Samuel S. Newton
    • 1
  1. 1.Department of PsychiatryYale University School of MedicineNew HavenUSA

Personalised recommendations